Fourchette de valorisation composite · prudent €58–€66 / raisonnable €67–€90 / optimiste €98–€110. À €75.07, Dans la fourchette de valeur intrinsèque raisonnable.
Nexviazyme met the primary and all secondary endpoints in a phase 3 study for infantile-onset Pompe disease.
Possible impact:May affect expectations for rare-disease label expansion and a planned US regulatory submission.
The EU opened an antitrust probe into Sanofi's Efluelda flu vaccine marketing, examining whether it disparaged rival vaccine Fluad.
Possible impact:May affect compliance risk, possible fine exposure, and reputation expectations for Sanofi's vaccine business in Europe.
EU regulators opened an antitrust probe into whether Sanofi’s Efluelda flu vaccine marketing disparaged a rival vaccine.
Possible impact:May affect vaccine compliance risk, potential fine expectations, and investor sentiment.
The European Commission opened an antitrust probe into Sanofi's marketing of Efluelda, examining alleged disparagement of a rival flu vaccine.
Possible impact:May affect expectations for vaccine compliance risk, possible penalties, and investor views on management execution.
Cenrifki was approved in the EU for secondary progressive multiple sclerosis without relapses.
Possible impact:May improve expectations for Sanofi’s neuroimmunology pipeline, with liver-safety monitoring remaining important.
Automatically summarized from public sources; for context only, not investment advice.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Pas encore d'analyse sur cette valeur dans votre langue.
